8-K: C4 Therapeutics Announces Positive Cemsidomide Data and First Quarter 2025 Financial Results

C4 Therapeutics reports promising early clinical data for cemsidomide in multiple myeloma and provides a financial update for the first quarter of 2025.

Summary

• C4 Therapeutics announced its first quarter 2025 financial results and provided business updates, including positive data from its cemsidomide clinical trial.
• The company reported revenue of $7.2 million for the first quarter of 2025, compared to $3.0 million for the same period in 2024.
• R&D expenses were $27.1 million, up from $22.5 million in the first quarter of 2024, while G&A expenses decreased to $9.3 million from $10.3 million.
• The net loss for the quarter was $26.3 million, or $0.37 per share, compared to a net loss of $28.4 million, or $0.41 per share, in the first quarter of 2024.
• As of March 31, 2025, C4 Therapeutics had $234.7 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2027.
• Cemsidomide's Phase 1 dose escalation in multiple myeloma is complete, with a 50% overall response rate (ORR) observed at the 100 g dose level.
• One patient at the 100 g dose level achieved a minimal residual disease negative complete response after progressing on two prior T-cell engager therapies.
• The company expects to receive regulatory feedback on registrational development for cemsidomide by mid-year 2025 and plans to initiate the next phase of development in early 2026.
• C4T has decided to seek partnership opportunities to advance the BRAF program CFT1946 and will not advance it beyond the ongoing Phase 1 trial.
• The Phase 1 dose escalation trial for CFT8919, in partnership with Betta Pharmaceuticals, continues to advance in Greater China.
• C4T achieved two preclinical milestones under the Roche collaboration, earning $4 million in payments.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, driven by promising clinical data for cemsidomide and a solid financial position. However, the decision to seek a partner for the BRAF program and the net loss temper the overall sentiment.

Positives

• Cemsidomide shows promising response rates in multiple myeloma, with a 50% ORR at the 100 g dose.
• The company has a strong cash position, providing a runway into 2027.
• Revenue increased significantly in the first quarter of 2025 compared to the same period in 2024.
• The Roche collaboration is progressing, with two preclinical milestones achieved.
• Cemsidomide remains well-tolerated with manageable neutropenia.

Negatives

• The company experienced a net loss of $26.3 million for the first quarter of 2025.
• R&D expenses increased compared to the first quarter of 2024.
• C4T will not advance CFT1946 beyond Phase 1 and will seek partnership opportunities.

Risks

• The development of cemsidomide and other product candidates is subject to risks and uncertainties related to clinical trials and regulatory approvals.
• The company's ability to fund future operations depends on securing sufficient capital on acceptable terms.
• The company may not be able to replicate results achieved in preclinical studies or clinical trials in future studies or trials.
• The company may not receive regulatory advice or authorization related to clinical trials.

Future Outlook

C4 Therapeutics expects its cash, cash equivalents, and marketable securities as of March 31, 2025, will enable the company to fund its operating plan into 2027. The company plans to present data from completed cemsidomide Phase 1 dose escalation in MM in Q3 2025, complete cemsidomide Phase 1 dose escalation in NHL and present data in Q4 2025, open expansion cohort(s) in PTCL in the second half of 2025, and enable initiation of the next phase of clinical development for cemsidomide with new studies expected to initiate in early 2026.

Management Comments

• Andrew Hirsch, president and chief executive officer of C4 Therapeutics, stated that 2025 has been marked by focused execution across C4T to generate key data to optimize development plans across the clinical portfolio.
• He also mentioned that the company is prioritizing progressing cemsidomide to the next phase of development to realize its potential to be a best-in-class IKZF1/3 degrader.
• Hirsch noted the company remains focused on maximizing its cash runway, which includes advancing cemsidomide and pursuing its internal discovery pipeline.

Industry Context

C4 Therapeutics is operating in the competitive field of targeted protein degradation, aiming to develop novel therapies for cancer and other diseases. The company's focus on IKZF1/3 degradation in multiple myeloma and non-Hodgkin's lymphoma aligns with the industry's interest in immunomodulatory drugs and targeted therapies. The decision to seek partnership for the BRAF program reflects the challenges and capital requirements of advancing multiple clinical programs simultaneously.

Comparison to Industry Standards

• The 50% ORR observed with cemsidomide in heavily pre-treated multiple myeloma patients is competitive with other emerging therapies in this space, such as bispecific antibodies and CAR-T cell therapies.
• The company's cash runway into 2027 provides a degree of financial stability compared to other biotech companies that may need to raise capital sooner.
• The decision to partner the BRAF program is similar to strategies employed by other biotech companies to focus resources on core assets and leverage external expertise.
• Companies like Arvinas and Kymera Therapeutics are also focused on targeted protein degradation, but with different targets and therapeutic areas.

Stakeholder Impact

• Shareholders may react positively to the promising clinical data for cemsidomide and the extended cash runway.
• Employees may be affected by the decision to seek a partner for the BRAF program, potentially leading to restructuring or reallocation of resources.
• Patients with multiple myeloma and non-Hodgkin's lymphoma may benefit from the development of cemsidomide as a new treatment option.
• The company's collaborations with Merck KGaA and Roche benefit those partners by providing access to C4 Therapeutics' technology and expertise.

Next Steps

• Present data from completed cemsidomide Phase 1 dose escalation in MM in Q3 2025.
• Complete cemsidomide Phase 1 dose escalation in NHL and present data in Q4 2025.
• Open expansion cohort(s) in PTCL as part of the current cemsidomide Phase 1/2 trial in the second half of 2025.
• Enable initiation of the next phase of clinical development for cemsidomide with new studies expected to initiate in early 2026.
• Utilize data from Phase 1 dose escalation trial in Greater China to inform ex-China clinical development for CFT8919 by year-end 2025.
• Present and publish preclinical work from internal pipeline and TORPEDO platform in 2025.
• Advance internal and collaboration programs to key discovery milestones in 2025.

Key Dates

Keywords

cemsidomide, multiple myeloma, targeted protein degradation, clinical trial, financial results, CFT8919, CFT1946, Roche, IKZF1/3, EGFR L858R, BRAF V600